- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05949671
Evaluation of the Effect of Gluten-Free Diet and Mediterranean Diet
Evaluation of the Effect of Gluten-Free Diet and Mediterranean Diet on the Autoimmune System in Patients With Hashimoto's Thyroid
Background: Hashimoto's Thyroiditis is an autoimmune disease that attacks thyroid cells through cell- and antibody-mediated immune processes and is characterized by the production of thyroid autoantibodies. In hashimoto, antithyroid peroxidase antibodies are increased and thyroid stimulating hormone levels are elevated. A gluten-free diet regulates thyroid autoimmunization by decreasing the concentration of antibodies. The Mediterranean diet also reduces disease-related oxidative stress parameters in patients with hashimoto's thyroid due to its anti-inflammatory effects.
Aims: To evaluate the short-term effects of Mediterranean, gluten-free and Mediterranean gluten-free dietary patterns on thyroid function and autoantibody levels of patients.
Study Design: Prospective, single-blind randomized controlled trial including case and control groups Methods: The 40 patients with hashimato thyroiditis included in the study were randomly divided into 4 different groups as gluten-free, Mediterranean, Mediterranean gluten-free and control group for 12 weeks. Thyroid function tests and autoantibody levels were analyzed at the beginning and end of the study. In addition, anthropometric measurements were taken at the beginning and end of the study and food consumption records and food consumption frequencies were evaluated.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey
- Istınye University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- To apply to the Internal Diseases (Internal Medicine) outpatient clinic, to be diagnosed with hashimato thyroid (HT) by a physician and to be between the ages of 18-65,
- No diagnosis of any autoimmune system disease other than HT that may adversely affect the study,
- No symptoms of celiac disease and no diagnosis,
- Not following a gluten-free diet in the last three months,
- Not being diagnosed with an eating behaviour disorder,
- Not having any communication problems,
- Signing the informed consent form,
- Having had a thyroid ultrasound within the last six months,
- Elevated anti -TPO (>5.61 IU/ml) and anti Tg (>4.11 IU/ml),
- To have TSH, Free T3 and Free T4 tests performed,
- Body Mass Index to be in the range of 18.5 kg/m2 - 30 kg/m2 <,
- Not losing 5% and/or more body weight in the last month
Exclusion Criteria:
- - Under 18 years of age and over 65 years of age,
- Having thyroid disease other than HT,
- Having a diagnosis of autoimmune system disease other than HT that may adversely affect the study,
- Symptoms and/or diagnosis of celiac disease,
- To have been diagnosed with non-celiac gluten sensitivity,
- Following a gluten-free diet within the last three months,
- A diet therapy that has an effect on the autoimmune system within the last three months,
- Being diagnosed with eating behaviour disorder,
- Having any communication problems,
- Not signing the informed consent form,
- Failure to adapt to the work during the working period, to be in a situation/behaviour that may adversely affect the work,
- To have applied any nutritional intervention during the last three months prior to the study,
- Being pregnant or breastfeeding,
- Taking supplements such as selenium, zinc, vitamin D and/or iodine, which may affect the course of the study,
- To have received cancer treatment and / or to be receiving cancer treatment,
- Having other endocrine or metabolic diseases (e.g. diabetes, cardiovascular diseases),
- Diagnosed with a disease lasting more than 4 months in the last 12 months and other specialised dietary / compositionally different dietary patterns (e.g. high protein, ketogenic, low energy content < 1000 kcal/day),
- Body Mass Index <18.5 kg/m2 or BMI≥30 kg/m2,
- Loss of 5% and/or more body weight in the last month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Mediterranean groups
This study is a prospective, single-blind study including case and control groups.
Before the study started, participants were informed about the benefits and risks of the study.
Participants were randomly divided into four different groups (MD, GFD, MGFD and control group).
The intervention groups (MD group (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted.
Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
|
This study is a prospective, single-blind study including case and control groups.
Before the study started, participants were informed about the benefits and risks of the study.
Participants were randomly divided into four different groups (MD, GFD, MGFD and control group).
The intervention groups (MD group (n=10), GFD (n=10), MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted.
Patients in the control group (n=10) did not receive any special dietary intervention.
Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
|
|
Experimental: Gluten-Free groups
This study is a prospective, single-blind study including case and control groups.
Before the study started, participants were informed about the benefits and risks of the study.
Participants were randomly divided into four different groups (MD, GFD, MGFD and control group).
The intervention groups (GFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted.
Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
|
This study is a prospective, single-blind study including case and control groups.
Before the study started, participants were informed about the benefits and risks of the study.
Participants were randomly divided into four different groups (MD, GFD, MGFD and control group).
The intervention groups (MD group (n=10), GFD (n=10), MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted.
Patients in the control group (n=10) did not receive any special dietary intervention.
Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
|
|
Experimental: Mediterranean Gluten-Free groups
This study is a prospective, single-blind study including case and control groups.
Before the study started, participants were informed about the benefits and risks of the study.
Participants were randomly divided into four different groups (MD, GFD, MGFD and control group).
The intervention groups (MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted.
Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
|
This study is a prospective, single-blind study including case and control groups.
Before the study started, participants were informed about the benefits and risks of the study.
Participants were randomly divided into four different groups (MD, GFD, MGFD and control group).
The intervention groups (MD group (n=10), GFD (n=10), MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted.
Patients in the control group (n=10) did not receive any special dietary intervention.
Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
|
|
No Intervention: control group
Patients in the control group (n=10) did not receive any special dietary intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the Effect of Gluten-Free Diet and Mediterranean Diet on the Autoimmune System in Patients with Hashimoto's Thyroid
Time Frame: May 2021-June2022
|
Diet group (MD group (n=10)) was administered weekly diets for 12 weeks by a dietitian according to personalised and daily energy needs and weight loss was not targeted.
|
May 2021-June2022
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the Effect of Gluten-Free Diet and Mediterranean Diet on the Autoimmune System in Patients with Hashimoto's Thyroid
Time Frame: May 2021-May 2022
|
Diet group (MD group (n=10)) was administered weekly diets for 12 weeks by a dietitian according to personalised and daily energy needs and weight loss was not targeted.
|
May 2021-May 2022
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mutlu Tuçe Ülker, Dr, Acibadem University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACU-BES-SBF-MUTLUTUCEULKER-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hashimoto Disease
-
Ankara City Hospital BilkentCompleted
-
Aristotle University Of ThessalonikiCompleted
-
The Cleveland ClinicActive, not recruiting
-
Sykehuset TelemarkHelse Stavanger HF; Haukeland University HospitalCompletedHashimoto's DiseaseNorway
-
Qianfoshan HospitalNot yet recruitingHashimoto Thyroiditis
-
National Taiwan University HospitalCompleted
-
Halic UniversityNot yet recruiting
-
National Taiwan University HospitalUnknownHashimoto's ThyroiditisTaiwan
-
Mansoura UniversitySaudi German Hospital - MadinahNot yet recruitingThyroiditis | Hashimoto Thyroiditis | Subacute Thyroiditis
Clinical Trials on mediterranean, gluten-free and mediterranean gluten-free diet intervention
-
Massachusetts General HospitalTerminated
-
University Hospital, Clermont-FerrandInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement and other collaboratorsRecruitingAnkylosing SpondyloarthritisFrance
-
Sahlgrenska University Hospital, SwedenCompletedIrritable Bowel SyndromeSweden
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...UnknownCeliac DiseaseItaly
-
University of LahoreCompletedMetabolic Syndrome | Lipid Profile | Weight Change, Body | HOMA-IRPakistan
-
University of CopenhagenRigshospitalet, DenmarkCompletedThe Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With CISMultiple Sclerosis | Clinically Isolated Syndrome | Optic NeuritisDenmark
-
University Hospital of North NorwayThe Norwegian Coeliac Society; The Gastrointestinal Research Foundation, University...Completed
-
University of Maryland, BaltimoreCompletedCeliac Disease | Gluten SensitivityUnited States
-
The Hospital for Sick ChildrenCompletedDiabetes Mellitus, Type 1 | Celiac DiseaseCanada
-
McMaster UniversityUnknownCeliac Disease | GERD | Barrett Esophagus | Gluten Sensitivity